Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inogapendekin alfa is recombinant human IL-15 with an amino acid substitution (Asn72Asp/N72D) that enhances its agonist activity at the IL-15R¦Â¦Ãc complex. IL-15N72D increases biological activity by 4-5-fold compared to the wild type cytokine. Inogapendekin alfa enhance the immunity and inhibit viral infections.
| Products Name (INN Index) | Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 |
|---|---|
| INN Name | nogapendekin alfa |
| Target | IL15RA |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IL15 (interleukin 15, IL-15) variant N72>D |
| VD LC | IL15 (interleukin 15, IL-15) variant N72>D |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Altor?BioScience (FL USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL15RA |
| Package |
